Submit Article
Back to Journal

SM Journal of Hepatitis Research and Treatment

The Impact of IL28B Single Nucleotide Polymorphism on Antiviral Response in HCV Genotype 2 or 3

[ ISSN : 2573-3672 ]

Abstract
Details

Received: 22-Nov-2016

Accepted: 16-Jan-2017

Published: 19-Jan-2017

Research Article | Volume 3 - Issue 1 | Article DOI : 10.36876/smjhrt.1010

Download PDF

Deise Machado dos Santos¹, Nayle Maria Oliveira da Silva²*, Rubens Caurio Lobato³, Luanna Elisa Liebscher Vidal⁴, Elisa Moraes Batista⁵, Mateus da Rocha Rodrigues⁶, Carolina Fischer Cunha⁶, Andrea Delfino Torres⁷, Vanusa Pousada da Hora⁸, Andre Felipe Andrade dos Santos⁹ and Ana Maria Barral de Martinez⁸

¹Gastroenterologist, undertaking Master’s in Health Sciences in the Federal University of Rio Grande
²Professor in the Institute Educar Brazil, Don Bosco College
³Department of Health Sciences, Federal University of Rio Grande
?Department of Genetics, Federal University of Rio de Janeiro
?Pharmacist at the Center of application and monitoring of injectable drugs
?Medical Interns in general practice in the Hospital Dr. Miguel Riet Corrêa Jr
?Nurse at the Center of application and monitoring of injectable drugs
?Associate Professor at the Federal University of Rio Grande
?Associate Professor at the Federal University of Rio de Janeiro

Corresponding Author:

Naylê Maria Oliveira da Silva, Health Sciences-Professor in the Institute Educar Brazil-Don Bosco CollegePelotas – Rio Grande do Sul/Brazil, Tel: 55 53 91329843, Email: nayleoliveira@gmail.com

Keywords

nterleukin 28; Hepatitis C; Polymorphism; Hepatic fibrosis; SVR

Abstract

Background and Aim: This study aimed to relate the impact of IL-28B SNP in HCV genotype 2 (GT2) and 3 (GT3) associated with the degree of liver fibrosis, according to Metavir score and sustained virologic response (SVR).

Methods: This cross-sectional study conducted between January 2012 and December 2014, which involved 103 patients treated in the center of application and monitoring of injectable drugs from the city of Rio Grande/ RS-Brazil. The analysis of the region rs12979860 IL-28B, PCR was performed according to the technique of Moreira et al, 2012.

Results: Caucasian patients showed 3.15 times greater chance of having SVR than the non-Caucasian ones (p = 0.046). Patients with higher degrees of fibrosis (F3/F4) obtain lower rates of SVR. Among the GT3, SVR was 84% in patients with lower degrees of fibrosis (F0/F1/F2) and 67.7% in patients with higher degrees of fibrosis. The GT3 showed fibrosis F3/F4 almost twice more than those with GT2 (59.7% versus 33.3%). Patients with a IL-28B CC genotype had about 3.8 times higher chance to present SVR compared to those patients with IL-28B TT genotype. The chance for advanced fibrosis in patients with TT genotype of the IL-28B was 3.6 times higher than in patients with CC genotype.

Conclusions: The results obtained in this study indicate the need of permanent search for predictive response factors to antiviral treatment of genotype 3 patients, especially those with higher degrees of fibrosis, even in the age of direct-acting antivirals.

Citation

dos Santos DM, da Silva NMO, Lobato R, Vidal LEL, Batista EM, Rodrigues MR, et al. The Impact of IL28B Single Nucleotide Polymorphism on Antiviral Response in HCV Genotype 2 or 3. SM J Hepat Res Treat. 2017; 3(1): 1010. https://dx.doi.org/10.36876/smjhrt.1010